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Apolipoprotein E (APOE) is the only confirmed susceptibility gene for late-onset Alzheimer disease (AD). In a recent
genomic screen of 54 families with late-onset AD, we detected significant evidence for a second late-onset AD locus
located on chromosome 12 between D12S373 and D12S390. Linkage to this region was strongest in 27 large
families with at least one affected individual without an APOE-4 allele, suggesting that APOE and the chromosome
12 locus might have independent effects. We have since genotyped several additional markers across the region,
to refine the linkage results. In analyzing these additional data, we have addressed the issue of heterogeneity in the
data set by weighting results by clinical and neuropathologic features, sibship size, and APOE genotype. When
considering all possible affected sib pairs (ASPs) per nuclear family, we obtained a peak maximum LOD score
between D12S1057 and D12S1042. Themagnitude and location of themaximumLOD score changedwhen different
weighting schemes were used to control for the number of ASPs contributed by each nuclear family. Using the
affected-relative-pair method implemented in GENEHUNTER-PLUS, we obtained a maximum LOD score between
D12S398 and D12S1632, 25 cM from the original maximum LOD score. These results indicate that family size
influences the location estimate for the chromosome 12 AD gene. The results of conditional linkage analysis by
use of GENEHUNTER-PLUS indicated that evidence for linkage to chromosome 12 was stronger in families with
affected individuals lacking an APOE-4 allele; much of this evidence came from families with affected individuals
with neuropathologic diagnosis of dementia with Lewy bodies (DLB). Taken together, these results indicate that
the chromosome 12 locus acts independently of APOE to increase the risk of late-onset familial AD and that it
may be associated with the DLB variant of AD.
Introduction
Alzheimer disease (AD [MIM 104300]) is a progressive
neurodegenerative disorder with a complex etiology
comprising genetic and environmental factors. More
than 2 million individuals in the United States have AD;
this figure is projected to quadruple in the next 50 years,
as the population ages (Brookmeyer et al. 1998). Clin-
ically, AD causes progressive memory loss and alters
higher intellectual function (Guttman et al. 1999). Al-
though provisional diagnosis of AD may be made on
the basis of clinical symptoms, neuropathologic exam-
ination is required for confirmation of the diagnosis. At
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autopsy, AD is characterized by neurofibrillary tangles
in the neurons of the cerebral cortex and hippocampus
as well as by the deposition of amyloid in senile plaques
and cerebral blood vessels (Wisniewski et al. 1993).
Lewy bodies, the neuropathologic hallmark of Parkinson
disease, are found in 15%–20% of autopsied individuals
with a clinical diagnosis of probable AD (Hulette et al.
1995; McKeith et al. 1996). In a recent consensus paper
(McKeith et al. 1996), it was recommended that the
designation “dementia with Lewy bodies” (DLB) be used
to describe this finding. Whether DLB is a variant of AD
or is a separate yet phenotypically similar neurodege-
nerative disease is currently unknown.
Familial aggregation of AD has been noted for dec-
ades, suggesting a role for genes in the etiology of the
disease. The results of studies focusing on large families
with the rare, early-onset, autosomal dominant form of
the disease led to the discovery that mutations in the
amyloid precursor protein, presenilin 1, and presenilin
2 genes caused AD (Goate et al. 1991; Levy-Lahad et
al. 1995; Rogaev 1995; Sherrington et al. 1995). Studies
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of the more-common late-onset form of AD have de-
termined that the apolipoprotein E gene (APOE) is a
susceptibility factor for both late-onset familial AD and
sporadic AD (Corder et al. 1993; Saunders et al. 1993;
Strittmatter et al. 1993). Unlike the genes for early-onset
AD, APOE is not a sufficient cause of the disease but,
instead, modulates the risk of AD developing. The pres-
ence of the APOE-4 allele increases risk and decreases
age at onset of the disease, whereas the APOE-2 allele
has a protective function (Corder et al. 1993, 1994).
Despite success in the detection of genes associated with
AD, together these four genes explain !50% of the risk
of AD attributed to genetics, indicating that additional
AD loci exist (Farrer et al. 1997).
Recent research efforts have identified chromosome
12 as the most-promising location for a fifth AD gene.
The functional candidate gene, LRP1 (LDL receptor–
related protein), is located on chromosome 12q, and
noncoding LRP1 polymorphisms have been associated
with a slightly increased risk of AD in some studies
(Kang et al. 1997; Lendon et al. 1997; Wavrant-De-
Vrieze et al. 1997; Hollenbach et al. 1998; Kamboh et
al. 1998) but not in all (Clatworthy et al. 1997; Fallin
et al. 1997; Scott et al. 1998). In addition, the results
of our recent complete genomic screen (Pericak-Vance
et al. 1997) showed significant evidence for linkage to
a pericentromeric region of chromosome 12; subsequent
follow-up has detected evidence for linkage in a wider
region of the chromosome (Scott et al. 1999). Other
investigators have recently replicated linkage to chro-
mosome 12 (Rogaeva et al. 1998; Wu et al. 1998) in
independent samples, strengthening the argument that
an AD gene maps to this chromosome. Finally, the re-
sults of a study conducted with use of the National
Institute of Mental Health (NIMH) AD Genetics Ini-
tiative data set showed a significant association with an
insertion/deletion polymorphism in the a2-macroglob-
ulin gene (A2M), which is another functional candidate
gene for AD located on chromosome 12p (Blacker et
al. 1998). However, this association has not been rep-
licated either in several independent familial and case-
control samples (Dow et al. 1999; Rogaeva et al. 1999;
Rudrasingham et al. 1999) or in an independent ex-
amination of the publicly available NIMH AD Genetics
Initiative data set (Rogaeva et al. 1999). Therefore, it
appears likely that the AD gene located on chromosome
12 remains to be discovered. In the present study, we
refine our original linkage (Pericak-Vance et al. 1997)
by analyzing additional markers in the region, and we
address the issue of genetic heterogeneity in the data set
by weighting families by APOE genotype as well as by
clinical and neuropathologic features.
Material and Methods
Description of Sample
During the past 15 years, more than 200 families with
multiple individuals affected with AD (“multiplex fam-
ilies”) have been ascertained for genetic studies of late-
onset familial AD. All sampled individuals have had pos-
sible or probable AD diagnosed (by use of National In-
stitute of Neurological Disorders and Stroke/Alzheimer’s
Disease and Related Disorders Association [NINDS/
ADRDA] criteria [McKhann et al. 1984]) by a neurol-
ogist or by associated clinical personnel at the Joseph
and Kathleen Bryan Alzheimer’s Disease Research Cen-
ter (ADRC) at Duke University Medical Center
(DUMC), the Massachusetts General Hospital ADRC,
the University of California at Los Angeles Neuropsy-
chiatric Institute, or the Indiana Alzheimer’s Disease
Center National Cell Repository. Data collection and
analysis for this study were performed according to pro-
tocols reviewed and approved by the institutional review
boards of each participating institution.
A subset of 54 families was selected for a recently
completed genomic screen and follow-up (Pericak-Vance
et al. 1997) that implicated the region of chromosome
12 examined in more detail in the present study. A de-
scription of this data set may be found in the initial
report (Pericak-Vance et al. 1997). Participants in this
study are followed up longitudinally; clinical and neu-
ropathologic data are continuously updated, and the
most recent information was used in this analysis. Since
the 1997 report appeared, affection status has changed
for six individuals from six families: one individual with
a previously unclear status is now considered to be af-
fected, two unaffected individuals are now considered
to have unclear status, and three individuals that were
previously considered to be affected are now considered
to have unclear status. In addition, two unaffected in-
dividuals from a seventh family were added to the data
set. Therefore, although the data set used for this anal-
ysis contains the same families that were used in our
previous study, it is not identical in terms of clinical or
neuropathologic data.
Neuropathologic Studies
Consensus diagnostic criteria (McKhann et al. 1984)
for AD indicate that postmortem neuropathologic ex-
amination is necessary to establish a definite diagnosis
of AD. Therefore, autopsy confirmation of AD is ob-
tained for genetic-study participants whenever possible.
Assessment of AD neuropathology is performed accord-
ing to standard Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD) and National Institute on
Aging and the Reagan Institute (NIA–Reagan) criteria
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(Mirra et al. 1991; Hyman and Trojanowski 1997). Ad-
ditional examinations of cortical and subcortical regions
for Lewy bodies follow consensus guidelines for the neu-
ropathologic diagnosis of DLB (McKeith et al. 1996).
The presence of Lewy bodies in the brain tissue housed
in the DUMC ADRC Brain Bank is confirmed by stain-
ing with a-synuclein antibodies. Neuropathologic ex-
amination established a diagnosis of definite AD in at
least one individual in 32/54 families studied.
Genotyping
Genomic DNA was extracted from whole blood by
use of methods described elsewhere (Pericak-Vance et al.
1991). Marker genotyping was performed by means of
fluorescence imaging with Molecular Dynamics SI or
Hitachi FMBIO fluoroimagers (Vance and Ben Othmane
1998). Follow-up markers were selected for analysis
from such published sources as The Genome Database
and the Marshfield Medical Research Foundation, Cen-
ter for Medical Genetics, on the basis of high hetero-
zygosity, spacing in the candidate interval, and ease of
use in the laboratory.
Linkage Analysis
Initial two-point parametric linkage analysis of all fol-
low-up markers was performed by use of VITESSE
(O’Connell and Weeks 1995). As in the original linkage
report (Pericak-Vance et al. 1997), an autosomal dom-
inant, affecteds-only model with a 5% misdiagnosis cor-
rection was used. The disease-allele frequency was as-
sumed to be .001, and marker-allele frequencies were
estimated from a set of 50–100 unrelated white individ-
uals that were unaffected with AD. To assess linkage in
the presence of genetic heterogeneity, maximum heter-
ogeneity LOD scores (HLOD) were generated by use of
the HOMOG program (Ott 1999).
Nonparametric affected-sib-pair (ASP) analysis of the
data was performed by use of ASPEX (Hinds and Risch
1998). Extended pedigrees were broken down into nu-
clear families, and allele sharing among ASPs in each
nuclear family was examined. To control for the effect
of including multiple (dependent) ASPs in a nuclear fam-
ily, ASPEX may be limited to consider independent ASPs
(all affected pairs containing the first affected individual)
or only the first ASP per nuclear family. In each case,
ASPEX calculates a nonparametric maximum LOD
score (denoted as “MLS” by Hinds and Risch [1998])
that is interpreted in the same manner as is a parametric
LOD score (e.g., MLS 13 is considered significant evi-
dence for linkage). The performance of these three
weighting schemes was compared with use of the Spairs
statistic implemented in GENEHUNTER-PLUS (Kong
and Cox 1997), where the maximum LOD score (de-
noted as “LOD*” by Kong and Cox) is calculated from
estimates of allele sharing averaged across all possible
affected pairs.
Because several extended families contained affected
relative pairs other than sib pairs (Pericak-Vance et al.
1997), we selected GENEHUNTER-PLUS (Kruglyak et
al. 1996; Kong and Cox 1997) to perform multipoint,
nonparametric affected-relative-pair analysis. This ex-
tension of the GENEHUNTER program uses a hidden
Markov model to examine allele sharing either at mul-
tiple markers averaged across all possible pairs of af-
fected relatives (Spairs) or simultaneously across all af-
fected individuals in a pedigree (Sall). Because the Spairs
statistic is more similar, compared with the Sall statistic,
to the approach implemented in ASPEX and because it
is more robust in small samples, it was selected for use
in this analysis. The nonparametric-linkage (NPL) test
statistic is asymptotically normal, and statistical signif-
icance in large samples may be assessed by use of a
standard normal distribution. GENEHUNTER-PLUS
calculates a maximum-likelihood estimate of the NPL
statistic under either a linear model or an exponential
model; this estimate may then be converted to a “sem-
iparametric” LOD score: LOD* (Kong and Cox 1997).
For these analyses, LOD* was calculated by use of the
exponential model, which is more robust in smaller data
sets (Kong and Cox 1997). The maximum-likelihood
estimate of LOD* was limited to positive values of the
sharing parameter d, to ensure that positive LOD* scores
reflected excess sharing of alleles among affected family
members. Like the MLS statistic generated by ASPEX,
LOD* may be interpreted as a traditional LOD score,
and it is a less-conservative test of linkage in the presence
of missing data, compared with the NPL statistic. Be-
cause of computational constraints on pedigree size, un-
affected individuals were omitted from analysis in 13
pedigrees.
Potential interactions between APOE and chromo-
some 12 markers were evaluated by use of conditional
linkage methods outlined elsewhere (Cox et al. 1999).
Heterogeneity was assessed by weighting the by-family
results on the basis of the proportion of affected indi-
viduals lacking an APOE-4 allele (APOE-4 weighting).
Additive or epistatic interaction was tested by weighting
the by-family results on the basis of the proportion of
affected individuals possessing an APOE-4 allele (APOE-
4 weighting). A similar approach was used to explore
clinical heterogeneity. Families were stratified on the ba-
sis of the presence of neuropathologic features consistent
with DLB. Families with at least one member classified
as having DLB at autopsy ( ) were analyzed sepa-n = 8
rately from the other 46 families in the screen set. To
assess linkage conditional on both DLB and APOE, the
by-family results in each subset were weighted on the
basis of the proportion of affected individuals lacking
an APOE-4 allele. Statistical significance of conditional
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Table 1
Maximum Two-Point LOD Scores for Chromosome











D12S1695 0 0 .00
D12S89 4 0 .03
D12S391 7 .37 .39
D12S269 11 .75 .75
D12S1303 13 .19 .24
D12S373 17 1.30 1.43
D12S1650 19 1.20 1.20
D12S1688 23 1.26 1.26
D12S1057 25 1.25 1.30
D12S1042 29 1.48 1.71
q:
D12S1090 37 .82 .83
D12S1701 43 .65 .92
D12S368 47 .83 1.06
D12S270 48 1.06 1.51
D12S398 49 .39 .44
D12S1632 53 .07 .07
D12S75 57 .55 .60
D12S92 63 0 .03
D12S337 67 .06 .11
D12S64 70 0 .00
D12S88 75 1.09 1.14
D12S95 76 0 .00
D12S327 78 .26 .26
D12S377 83 .02 .02
D12S1091 96 .34 .35
a Used in multipoint analysis.
analyses was assessed by shuffling family-specific
weights to create a null distribution, as originally de-
scribed elsewhere (Cox et al. 1999).
Results
We genotyped 26 microsatellite markers spanning ∼100
cM of chromosome 12. Map distances and maximum
affecteds-only two-point LOD scores (with 5% misdi-
agnosis correction) assuming homogeneity (LOD) and
heterogeneity (HLOD) are presented in table 1. Maxi-
mum LOD scores were generally positive across the en-
tire region, and there was little difference in the maxi-
mum LOD score and HLOD for eachmarker.Maximum
LOD scores were 11.0 for 9/14 markers located within
our initial region of interest (Pericak-Vance et al. 1997),
with the peak LOD = 1.48 (HLOD 1.71) at marker
D12S1042.
Multipoint ASP analysis, by use of all possible ASPs,
generated a peak MLS of 2.21 between markers
D12S1057 and D12S1042, with a smaller peak near
D12S368 (fig. 1). The fluctuation in LOD scores for
chromosome 12 markers indicated possible genetic het-
erogeneity. Additional analyses were performed to con-
trol for differences in family size, the effect of APOE,
and neuropathologic features, as a means of addressing
heterogeneity.
In the first of these analyses, additional ASP analyses
were performed with the use of various weighting
schemes available in ASPEX and GENEHUNTER-
PLUS (fig. 1). Considering only independent ASPs, the
average of all ASPs, or only a single ASP per nuclear
family progressively decreases the evidence for linkage
at D12S1057. The most-extreme method of limiting the
influence of families with many ASPs (considering only
one ASP per nuclear family) also changes the location
estimate—a peak of 0.77 is obtained at marker
D12S1701. In the second analysis, GENEHUNTER-
PLUS was used to examine allele sharing averaged
across all affected relative pairs in each family. The over-
all LOD* plot (fig. 2) indicates that controlling for fam-
ily size shifts evidence for linkage in a fashion similar
to the use of only one affected relative pair in ASPEX;
the peak LOD* is 1.40 between markers D12S398 and
D12S1632.
To explore potential interactions between chromo-
some 12 linkage and APOE, we calculated LOD*, con-
ditional on the proportion of affected individuals in
each family possessing (APOE-4 weighting) or lacking
(APOE-4 weighting) an APOE-4 allele (fig. 2). Con-
sistent with a heterogeneity model, linkage results were
strongest when APOE-4 weighting was used (peak
LOD* = 2.43 at D12S1632). With APOE-4weighting,
LOD* scores remained low throughout the region (peak
LOD* = 0.48 at D12S368). Simulation determined that
the increase in LOD* seen with the use of APOE-4
weighting was statistically significant ( ), sinceP = .04
only 40/1,000 replicates produced LOD* 2.43.
In addition, we considered neuropathologic findings
as a second potential indicator of genetic heterogeneity
in this data set. Families were stratified into two groups,
on the basis of the presence of at least one family mem-
ber with autopsy findings consistent with the consensus
criteria for DLB (McKeith et al. 1996). The peak LOD*
= 2.18 that was obtained in the eight families with DLB
occurs between D12S1042 and D12S1090, and the re-
maining 46 families generate a peak LOD* = 0.58 at
D12S1632 (fig. 3). Simulation also determined that the
increase in LOD* in the families with DLB was statis-
tically significant ( ), with only 35/1,000 repli-P = .035
cates generating a LOD* 12.18.
The two groups of families (those with affected in-
dividuals lacking an APOE-4 allele and those with DLB)
with more evidence for linkage to chromosome 12 were
not independent, since six of the eight families with DLB
also had affected individuals lacking an APOE-4 allele.
Thus, we weighted the results in the eight families with
DLB and those in the other 46 families on the basis of
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Figure 1 Multipoint ASP analysis, by use of all possible ASPs, all independent ASPs, and one ASP per nuclear family, with the use of
ASPEX, and by the average across all ASPs, with the use of GENEHUNTER-PLUS.
the proportion of affected individuals lacking an APOE-
4 allele (fig. 4). In the families with DLB, the results
were not significantly different from those obtainedwith
stratification on DLB alone: a peak LOD* = 2.02 occurs
between D12S1042 and D12S1090. However, in the
remaining 46 families, the LOD* increases to 1.63 at
D12S1632, indicating that evidence for linkage remains
in this subset and is stronger when APOE-4 weighting
is used.
Discussion
Following up the original linkage of AD to chromosome
12 (Pericak-Vance et al. 1997), by genotyping of addi-
tional markers and by performing multipoint ASP anal-
ysis, has generated a maximum LOD score that is lower
than that originally obtained with a less-dense map of
markers. This finding is consistent with our previous
experience (Haines et al. 1993) in following up the initial
linkage of AD to chromosome 19 (Pericak-Vance et al.
1991). In that effort, genotyping of additional markers
and family members lowered the maximum LOD score
and widened the region of interest. The difference in
LOD scores was resolved by stratification of the families
on the basis of age at onset (thereby reducing genetic
heterogeneity), facilitating the identification of the
APOE gene as a risk factor for late-onset AD.
Our effort to control for family size in ASP analysis
clearly showed that including all ASPs in each nuclear
family changed the magnitude of the peak-location
score in this data set. The original peak MLS obtained
by use of all possible ASPs was at D12S1057, and this
MLS decreased with the use of each method of con-
trolling for multiple ASPs per nuclear family. This ob-
servation indicated that the localization of the gene to
12p was influenced by the contribution of multiple de-
pendent ASPs from several large families, possibly in-
flating the evidence for localization of the chromosome
12 gene to that region. In fact, when using the most-
stringent limitation of one ASP per nuclear family, we
found that the peak MLS was at D12S1701, ∼20 cM
away and on the other arm of the chromosome. To
further control for family size, we analyzed allele shar-
ing averaged across all ASPs in each family, by use of
the GENEHUNTER-PLUS program. Controlling for
family size in this manner supported the MLS results
when one ASP was used per family; the linkage peak
occurred on chromosome 12q, close to D12S1632. The
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Figure 2 Multipoint affected-relative-pair (LOD*) analysis that is either unweighted, APOE-4 weighted, or APOE-4 weighted.
results from both of these analyses suggest that analysis
of extended pedigrees broken down into nuclear fam-
ilies and failure to consider the dependencies among
ASPs may influence estimates of the disease-gene
location.
Analysis of the chromosome 12 data, conditional on
APOE genotype in affected family members, revealed
that linkage to chromosome 12 markers was concen-
trated in the families with affected members lacking the
APOE-4 allele (APOE-4 weighting), supporting a het-
erogeneity model. These data are consistent with those
from our previous report (Pericak-Vance et al. 1997),
in which we indicated that linkage to chromosome 12
was strongest in families with at least one affected in-
dividual with an APOE 2/2, 2/3, or 3/3 genotype.
We also considered separately the eight families
with at least one individual that met consensus neu-
ropathologic criteria for DLB (McKeith et al. 1996).
These eight families alone provide evidence for link-
age to a 20-cM interval bounded by D12S1057 and
D12S1701. In contrast, the remaining 46 families
show more-moderate evidence for linkage to the same
10-cM region on chromosome 12q, bounded by
D12S1701 and D12S1632, detected in the overall
data set.
These results indicate that estimates of the location
of the chromosome 12 AD gene vary by family size,
APOE genotype, and the presence of autopsy-confirmed
DLB in the family. However, it is unclear whether these
are independent effects in our data set or whether each
is associated with the same genetic-risk factor. Evalu-
ating linkage to chromosome 12 markers while consid-
ering APOE genotype and presence of DLB indicated
that much of the linkage information in the data set
comes from the six families with both DLB and indi-
viduals lacking an APOE-4 allele. However, the re-
maining 46 families without DLB still generate mod-
erate evidence for linkage to 12q when APOE-4
weighting is used.
Family size and presence of DLB in the family are
somewhat correlated in this data set, because the
chances of obtaining autopsy confirmation of AD for
at least one affected family member increases with both
the number of affected individuals in the family and the
length of time the family has been studied. In fact, the
presence of DLB in the 24 families with autopsy-con-
firmed AD but with no DLB cannot be ruled out, since
all affected individuals have not been autopsied. In ad-
dition, 22 families have no individuals with autopsy-
confirmed AD enrolled in the study, and, therefore, they
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Figure 3 Multipoint affected-relative-pair (LOD*) analysis, unweighted and stratified on the basis of presence or absence of DLB.
could not possibly be grouped with the families with
DLB. Taking this information into account, the pro-
portion of families with at least one individual with
autopsy-confirmed AD and with autopsy-confirmed
DLB (8/32 [25%]) is not much higher than previous
estimates of the frequency of DLB in probable AD
(10%–20%; Hulette et al. 1995; McKeith et al. 1996).
The strong correlation between chromosome 12 link-
age, APOE genotype, and presence of DLB makes it
difficult to determine which factor is more indicative of
the presence of the chromosome 12 locus: absence of
an APOE effect or presence of DLB.
Because of this correlation and because evidence for
linkage persists in the families without DLB when
APOE-4weighting is used, it would be unwise to strat-
ify families on the basis of presence or absence of DLB
and to focus fine-mapping efforts in the region of max-
imum linkage in each subset, without additional con-
firmation. Therefore, at present, the most-conservative
approach to finding the chromosome 12 AD gene is to
study the ∼30-cM region from D12S1057–D12S1632.
This region contains both the overall linkage peak on
chromosome 12q as well as the centromeric region im-
plicated by the eight families with DLB.
In effect, our efforts to fine map this region of linkage
have been an exercise in data mining. We have consid-
ered several potential factors (family size, APOE, and
presence of DLB) that may significantly alter observed
linkage between markers on chromosome 12 and AD,
and we have stratified our analyses accordingly, in an
attempt to identify a combination of factors that defines
a more-homogeneous subset of families in which there
is linkage to chromosome 12. The application of neural
networks and recursive partitioning to pattern recog-
nition in genetic analysis is currently being explored
(Falk et al. 1998; Lucek et al. 1998) and could provide
a framework for such data mining in the future. Even
so, the problem with data mining will remain: the so-
lution generated is often one of many possible solutions,
and, frequently, there is little evidence to recommend
one solution over the other.
The results described in the present study highlight
the difficulties of fine-mapping linked regions in a com-
plex disease, where genetic and clinical heterogeneity
likely impact estimates of the location and effect size.
In the case of chromosome 12–linked AD, several stud-
ies have reported linkage to chromosome 12 but have
highlighted different regions of maximum linkage (Per-
icak-Vance et al. 1997; Rogaeva et al. 1998; Wu et al.
1998; Kehoe et al. 1999) (fig. 5). Rogaeva and col-
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Figure 4 Multipoint affected relative pair (LOD*) analysis overall and stratified on the basis of presence or absence of DLB, with APOE-
4 weighting.
leagues (Rogaeva et al. 1998) studied a data set of 53
families that included both ASPs and large, multige-
nerational families with late-onset AD. Their linkage
studies focused on the region of chromosome 12 be-
tween D12S373 and D12S390 that was highlighted in
our original report (Pericak-Vance et al. 1997). Evi-
dence for linkage in their families was concentrated at
either end of the interval, with the strongest linkage
being located near D12S390. In contrast, others (e.g.,
Wu et al. 1998; Kehoe et al. 1999) have studied a
collection of 230 families with ASPs from the NIMH
AD Genetics Initiative data set. As part of a whole-
genome scan, they detected evidence for linkage on
chromosome 12p, near D12S391 (Wu et al. 1998; Ke-
hoe et al. 1999). This region contains the A2M gene,
which Blacker and colleagues had previously reported
as being associated with AD in the NIMH data set
(Blacker et al. 1998).
The different localizations of the chromosome 12 lo-
cus may be the result of differences in the ascertainment
of families and the manner in which the data sets were
stratified on the basis of APOE genotype. Although Ro-
gaeva et al (Rogaeva et al. 1998) studied families of
similar structure to those in our data set, they found
the strongest evidence for linkage in “APOE-4 positive”
families—contrary to our findings. However, they con-
sidered a family to be “APOE-4 positive” if 175% of
the individuals possessed an APOE-4 allele; four of these
families would have been classified as APOE-4 negative
in our original report (Pericak-Vance et al. 1997). Thus,
the results for APOE genotype may not conflict with
ours. Wu, Kehoe, and colleagues (Wu et al. 1998; Kehoe
et al. 1999) studied ASPs; the focus on nuclear families
produces a data set with a family structure that is dif-
ferent from ours and may influence their estimate of the
disease-gene location. The implication of the differences
among the three studies is not entirely clear. Each could
represent linkage to the same poorly localized gene. Al-
ternatively, two AD loci could be located on chromo-
some 12: all three studies support linkage to chromo-
some 12p in at least a subset of families, and both the
present study and a study done elsewhere (Rogaeva et
al. 1998) detect evidence for a locus on chromosome
12q. A potential resolution of the conflict may rest in
a consistent stratification of the families on the basis of
APOE and further stratification of the data sets on the
basis of presence of Lewy bodies in autopsied family
members.
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Figure 5 Regions of chromosome 12 implicated by the present study and by other studies (Rogaeva et al. 1998; Wu et al. 1998; Kehoe
et al. 1999).
In addition to difficulties in fine mapping posed by
heterogeneity, the results of recent studies indicate that
genotyping of additional markers provides additional
linkage information up to a map density of only 1–2
cM. The results of a recent study in sib pairs with mul-
tiple sclerosis (Feakes et al. 1999) showed that, once
markers reached a density of 2 cM, fine mapping done
by genotyping of additional markers became inefficient
because of the increasing likelihood that map or ge-
notyping errors would significantly lower themultipoint
LOD scores. Although our laboratory minimizes ge-
notyping errors by use of an extensive set of quality
control measures (Rimmler et al. 1998), our analyses
are still susceptible to errors in map order or distance.
These findings are consistent with our previous expe-
rience with chromosome 19 linkage in AD (Haines et
al. 1993).
Given these limitations of the use of linkage to refine
a candidate region in a genetically heterogeneous data
set, we believe that the approach that is likely to be
most effective in finding the AD gene on chromosome
12 is a candidate-gene- and linkage-disequilibrium-
based approach. Therefore, further fine mapping will
use family-based tests of association and linkage (such
as the sibling transmission/disequilibrium test) for reg-
ularly spaced microsatellite and single-nucleotide poly-
morphism markers in the region.
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